Survival for Malignant Glioma by RTOG Group

**Survival for Malignant Glioma by RTOG Group**
Group	Median	Alive at 2 Years
I	58 - 68 months	64 - 76%
II	37 - 57 months	67 - 68%
III	17 - 22 months	35 - 45%
IV	11 - 13 months	8 - 15%
V	8 - 9 months	3 - 6%
VI	4 - 5 months	3 - 4%

Note about using survival tables. Averages are only averages! Median survival is the time at which half the patients have died and half are still alive. These numbers are useful in that they give the decision-makers some general idea about what to expect and perhaps how aggressive to be with further therapy.

The person with the disease may or may not appreciate having these sort of numbers thrown in their face! But if they ask...

Survival for recurrent glioma is noted below

MRI Showing a Glioblastoma

Survival for Recurrent Glioma

Group	Criteria	Survival
Best	no steroids, KPS>90, not GBM	20.2 months
Medium	everything not in worst group	7.4 months
Worst	on steroids, age >50y, GBM histo	4.7 months

Prognostic factors for survival in adult patients with recurrent glioma enrolled on New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium phase I and II clinical trials

Abstract No:     1509 (ASCO 2005)
Author(s):    K. Carson, S. A. Grossman, J. D. Fisher, E. Shaw
Abstract:    Background: Prognostic factor analyses have proven useful in predicting outcome in patients (pts) with newly diagnosed malignant glioma. Similar analysis should be of benefit in recurrent glioma. Methods: Between 1995 and 2002, 333 adult pts were enrolled on 10 phase I or II clinical trials of systemic or local chemotherapy or brachytherapy for the treatment of recurrent glioma. The studies had similar inclusion criteria and were conducted within the NABTT Consortium. Survival time was calculated from start of treatment until death or last follow-up. 308 (93%) pts have died. Univariate Recursive partitioning analysis (RPA) was performed, and the log-rank test was used to group RPA classes with similar Kaplan-Meier survival estimates (KM). Results: Factors associated with an increased risk of death on univariate PH were increased age, lower KPS, initial and on-study histologies of GBM, steroid use, shorter time from original diagnosis to recurrence, and tumor location other than frontal. Factors that were not significant included gender, race, number of prior therapies, and anticonvulsant use. The final multivariate PH model included initial histology of GBM (relative risk (RR) = 2.04; 95% confidence interval (CI) = 1.49, 2.79), KPS < 90 (RR=1.35, 95% CI = 1.03, 1.77), 10 year increase in age (RR=1.20, 95% CI=1.06, 1.35), and steroid use (RR=1.56, 95% CI = 1.16, 2.10). RPA resulted in 5 classes, but 3 had similar KM and were combined. Median survival was poorest in GBM pts, age > 50, on steroids (4.7 months (m); 95% CI=3.5, 5.3), best in pts with initial histology other than GBM and KPS > 90 (20.2 m; 95% CI=12.2, 30.3), and was 7.4 m (95% CI=6.3, 9.0) for all other pts. Conclusions: Initial histology, KPS, age, and steroid use, are predictive of survival in recurrent glioma pts. Phase II and III clinical trials in pts with recurrent glioma should stratify by or adjust for these factors.